[
    {
        "id": "Case14017",
        "patient_info": "An otherwise healthy 7-week-old infant is being evaluated by the general pediatrician for a high-risk brief resolved unexplained event (BRUE) with recurrent witnessed seizure-like events, and whole exome sequencing (WES) has been ordered to evaluate for a possible genetic etiology. Prior karyotype testing was nondiagnostic. There is a family history of neurologic disease, specifically a maternal uncle reported to have a movement disorder with dystonia and ataxia, and pre-test genetic counseling was completed with plans for post-test follow-up. Testing is being pursued with coverage through BCBS_FEP."
    },
    {
        "id": "Case1778",
        "patient_info": "The patient is a 14-year-old adolescent referred by the primary care physician for genetic evaluation of an ocular coloboma, and whole exome sequencing (WES) has been requested for diagnostic clarification; prior fluorescence in situ hybridization testing was nondiagnostic."
    },
    {
        "id": "Case4604",
        "patient_info": "The patient is a six-year-old child referred by the primary care physician for evaluation of developmental delay and intellectual disability without a specific syndromic diagnosis suspected; prior chromosomal microarray (CMA) testing was nondiagnostic, and the family reports an older sibling with moderate to severe intellectual disability diagnosed by age 18; whole exome sequencing (WES) is being requested to evaluate for an underlying genetic cause, pre-test counseling has been completed with a genetic counselor with plans for post-test follow-up, and the family has coverage through BCBS_FEP."
    },
    {
        "id": "Case3422",
        "patient_info": "The patient is a 34-year-old referred by oncology for evaluation of congenital choanal atresia and consideration of whole-exome sequencing (WES) to assess for an underlying genetic etiology after a nondiagnostic chromosomal microarray (CMA); the patient has Cigna coverage, has seen a genetic counselor multiple times, and reports a mother who was diagnosed with breast cancer at age 50."
    },
    {
        "id": "Case10917",
        "patient_info": "The patient is an 8-week-old infant evaluated by a medical geneticist for persistent conjugated hyperbilirubinemia not attributed to total parenteral nutrition-associated cholestasis, and whole exome sequencing (WES) has been ordered to evaluate for an underlying genetic cause; family history is notable for an older sibling with multiple congenital anomalies, and Fragile X testing was previously performed and was nondiagnostic; pre-test counseling was completed with a genetic specialist and the family has coverage through UHC."
    },
    {
        "id": "Case18821",
        "patient_info": "The obstetrician requests fetal whole exome sequencing (WES) at 22 weeks' gestation after prenatal imaging identified findings concerning for multiple congenital anomalies affecting different organ systems, and the test is intended to evaluate a possible genetic etiology to inform perinatal counseling and management. Family history is notable for a maternal aunt reported to have dysmorphic features. There is no prior genetic testing and no documentation of pre-test genetic counseling, and the patient has coverage through the Blue Cross Blue Shield Federal Employee Program (BCBS_FEP)."
    },
    {
        "id": "Case13",
        "patient_info": "The newborn is being evaluated by the general pediatrician for multiple congenital anomalies that do not fit a well-delineated genetic syndrome and has been referred for whole exome sequencing (WES) after karyotype testing was nondiagnostic, there is a family history of a sibling with unexplained developmental regression unrelated to autism or epilepsy, pre-test genetic counseling was completed and post-test follow-up is planned, and testing will be submitted with coverage through BCBS_FEP."
    },
    {
        "id": "Case8621",
        "patient_info": "A 2-year-old child with a complex neurodevelopmental disorder with autism is undergoing evaluation with whole exome sequencing (WES) to seek a unifying diagnosis after prior chromosomal microarray (CMA) testing was nondiagnostic; the test was ordered by the child\u2019s oncologist and is planned with coverage through UHC, the family reports an uncle with a congenital anomaly as relevant family history, and the family has met with a genetic counselor multiple times with pre-test counseling completed and plans for post-test follow-up."
    },
    {
        "id": "Case8051",
        "patient_info": "An infant of 5 weeks with a major congenital cardiac anomaly is being evaluated with whole exome sequencing (WES) ordered by the family medicine physician, and prior fluorescence in situ hybridization testing was nondiagnostic; the history is notable for a mother with short stature raising concern for a growth-related genetic condition, the family completed pre-test genetic counseling and will follow up after results, and testing is being pursued to clarify the etiology of the cardiac defect and potential syndromic associations with billing through BCBS_FEP."
    },
    {
        "id": "Case13517",
        "patient_info": "The 16-year-old patient was referred by a developmental pediatrician for evaluation of conjugated hyperbilirubinemia not attributable to total parenteral nutrition\u2013associated cholestasis, and whole exome sequencing (WES) was ordered to evaluate for an underlying genetic cause given a sibling with laboratory abnormalities suggestive of an inborn error of metabolism. Fragile X testing was previously performed and was nondiagnostic. Pre-test counseling was completed with a genetic counselor and post-test counseling is planned, and testing will be billed through UHC."
    },
    {
        "id": "Case3359",
        "patient_info": "The patient is a 4-year-old child referred by a developmental pediatrician for evaluation of significant hypotonia and ongoing developmental concerns; chromosomal microarray (CMA) testing was previously performed and was nondiagnostic, and there is a family history notable for a sibling with developmental delay. Whole exome sequencing (WES) is being requested to evaluate for an underlying genetic etiology, pre-test counseling has been completed with a genetic counselor on multiple occasions, and plans for post-test follow-up and care coordination are in place with coverage through UHC."
    },
    {
        "id": "Case2496",
        "patient_info": "A prenatal evaluation at 32 weeks' gestation has been requested by a neonatologist for whole exome sequencing (WES) with coverage through UHC because of parental consanguinity and concern for autosomal recessive conditions, there is a reported family history of sudden unexplained death in a sibling before age 35, prior fluorescence in situ hybridization testing was nondiagnostic, and no genetic counseling has been completed, so WES is being pursued to assess risk for potential postnatal outcomes based on fetal imaging and to guide perinatal planning."
    },
    {
        "id": "Case8485",
        "patient_info": "An 8-year-old child with hypotonia first noted in infancy is being evaluated by the general pediatrician for persistent motor delay and evolving tone abnormalities, and whole exome sequencing (WES) has been ordered to investigate a possible genetic etiology; prior Fragile X testing was nondiagnostic, the family reports a sibling with autism spectrum disorder, pre-test genetic counseling was not performed, and testing will be submitted with coverage through Cigna."
    },
    {
        "id": "Case5674",
        "patient_info": "A 9-year-old child with persistent seizures is being evaluated by a general practitioner and has had multiple visits with a genetic counselor; a prior chromosomal microarray (CMA) was nondiagnostic, and the team plans whole exome sequencing (WES) to investigate a possible genetic epilepsy syndrome given a family history notable for sudden unexplained death in an uncle before age 35, with testing requested under BCBS_FEP and arrangements for post-test follow-up with genetics."
    },
    {
        "id": "Case3494",
        "patient_info": "The six-week-old infant was referred by the general pediatrician for genetic evaluation because of a congenital abnormality affecting at least one organ system with concern for an evolving complex neurodevelopmental disorder; no prior genetic testing has been performed, and there is a family history of dysmorphic features in a sibling, so whole exome sequencing (WES) is being requested for diagnostic clarification, genetic counseling was declined by the family, and coverage is through Cigna."
    },
    {
        "id": "Case7297",
        "patient_info": "This 3-year-old child was referred by a family medicine physician for evaluation of multiple congenital anomalies affecting different organ systems; prior karyotype testing was nondiagnostic and whole exome sequencing (WES) is being pursued to identify an underlying genetic etiology, the family reports a maternal aunt with ovarian cancer which raises concern for a possible familial predisposition, pre-test counseling was completed with a genetic specialist with plans for post-test follow-up, and the family has coverage through UHC and consents to WES to guide diagnosis, management, and cascade testing if indicated."
    },
    {
        "id": "Case9978",
        "patient_info": "The 53-year-old patient is undergoing whole exome sequencing (WES) at the request of the neurologist to evaluate an epileptic encephalopathy that began before age three and has persisted into adulthood; Fragile X testing was previously performed and was nondiagnostic. The patient has a brother with an inborn error of metabolism, has coverage through UHC, and completed pre-test counseling with a genetic counselor with plans for post-test follow-up."
    },
    {
        "id": "Case4196",
        "patient_info": "The patient is a 10-year-old referred by a cardiologist for evaluation of apparent nonsyndromic developmental delay and intellectual disability, and whole exome sequencing (WES) is being requested as the next diagnostic step; prior fluorescence in situ hybridization (FISH) testing was nondiagnostic, and there is a family history of a brother who was diagnosed with moderate to severe intellectual disability in childhood, pre-test genetic counseling has been completed with plans for post-test follow-up, and coverage is through the Blue Cross Blue Shield Federal Employee Program (BCBS_FEP)."
    },
    {
        "id": "Case14141",
        "patient_info": "The patient is a 7-year-old referred by an oncologist for evaluation of multiple congenital anomalies and whole exome sequencing (WES) is planned to investigate an underlying genetic etiology, with prior chromosomal microarray (CMA) testing reported as nondiagnostic; there is a family history of global developmental delay in a sibling, coverage is through the Blue Cross Blue Shield Federal Employee Program (FEP), and pre-test genetic counseling has been completed with arrangements for post-test counseling and follow-up."
    },
    {
        "id": "Case18882",
        "patient_info": "An 8-year-old child is referred by a developmental pediatrician for evaluation of multiple congenital anomalies affecting several organ systems, and whole exome sequencing (WES) is being requested with coverage through UHC; prior fluorescent in situ hybridization (FISH) testing was nondiagnostic, the family reports that the mother has long QT syndrome, and the family declined pre-test genetic counseling but agreed to proceed with testing with plans to coordinate post-test counseling to review results and management."
    },
    {
        "id": "Case5230",
        "patient_info": "The 15-year-old adolescent was referred by neurology for whole exome sequencing (WES) to evaluate a congenital anomaly after a nondiagnostic chromosomal microarray (CMA). There is a family history of an inborn error of metabolism in a sibling, the patient has coverage through UHC, and genetic counseling was declined at this time."
    },
    {
        "id": "Case11124",
        "patient_info": "An infant is presenting for evaluation of developmental delay and whole-exome sequencing (WES) has been ordered with coverage through UHC, following referral by an oncologist; pre-test counseling was completed and post-test genetic counseling is planned after results are returned. Prior fluorescence in situ hybridization testing was nondiagnostic. The family history is notable for an older sibling who had significant hearing impairment diagnosed in childhood, which raises concern for a hereditary etiology and supports comprehensive exomic testing."
    },
    {
        "id": "Case8288",
        "patient_info": "Fetal imaging at 36 weeks' gestation is concerning for a major congenital cardiac anomaly and the pregnancy was referred by a developmental pediatrician for genetic evaluation. A chromosomal microarray (CMA) was previously performed and was nondiagnostic. There is a family history of an inborn error of metabolism affecting an older sibling, and the parents have had multiple sessions with a genetic counselor. Given the late-gestation identification of a significant cardiac malformation and the nondiagnostic CMA, whole exome sequencing (WES) is being pursued to evaluate for an underlying genetic etiology that could inform perinatal and postnatal management, with coverage through UHC noted."
    },
    {
        "id": "Case7376",
        "patient_info": "The patient is a 73-year-old referred by a neurologist for evaluation of a major abnormality involving at least one organ system that remains unexplained, and whole exome sequencing (WES) has been ordered for diagnostic clarification. Prior fluorescent in situ hybridization testing was nondiagnostic. The patient reports that a sister had triple negative breast cancer, which raises concern for an underlying heritable predisposition. Pre-test counseling was completed with a genetic specialist and testing will proceed with coverage through UHC."
    },
    {
        "id": "Case7682",
        "patient_info": "This 9-year-old child was referred by a developmental pediatrician for evaluation of multiple congenital abnormalities affecting different organ systems and whole exome sequencing (WES) is being requested to identify a potential genetic cause; prior karyotype testing was nondiagnostic, there is a family history of developmental delay in a sibling, and pre-test counseling was completed with a genetic specialist with plans for post-test follow-up, and the family has coverage through UHC."
    },
    {
        "id": "Case19905",
        "patient_info": "The patient is a 3-year-old referred by the developmental pediatrician for evaluation of multiple congenital anomalies and is being considered for whole exome sequencing (WES) with coverage through UHC; prior karyotype testing was nondiagnostic, there is a family history notable for a mother with long QT syndrome, and no genetic counseling has been conducted to date."
    },
    {
        "id": "Case2847",
        "patient_info": "A 5-week-old infant was referred by cardiology after a high-risk brief resolved unexplained event that required cardiopulmonary resuscitation, and whole exome sequencing (WES) is being pursued to evaluate for an underlying genetic etiology; prior chromosomal microarray (CMA) testing was nondiagnostic. There is a family history of the mother having a persistent and severe immunologic or hematologic disorder, and the family has coverage through BCBS FEP. Pre-test counseling was completed with a genetic counselor and plans are in place for post-test follow-up."
    },
    {
        "id": "Case10529",
        "patient_info": "The child is a 6-year-old with apparent nonsyndromic developmental delay and intellectual disability who was referred by neurology for genetic evaluation; Fragile X testing was previously performed and was nondiagnostic, and there is a family history of neurologic disease in a maternal uncle with dystonia and ataxia. The family has seen a genetic counselor multiple times and pre-test counseling is complete with plans for post-test follow-up, and whole exome sequencing (WES) is being pursued with coverage through UHC."
    },
    {
        "id": "Case16487",
        "patient_info": "The newborn is being evaluated for a high-risk brief resolved unexplained event (BRUE) characterized by recurrent events in the absence of respiratory infection, and whole exome sequencing (WES) has been ordered by the oncologist following nondiagnostic fluorescence in situ hybridization (FISH) testing, the family history is notable for a maternal aunt with a persistent severe immunologic or hematologic disorder, the infant has coverage through UHC, and pre-test counseling was completed with plans for post-test genetic follow-up."
    },
    {
        "id": "Case811",
        "patient_info": "The patient is a 7-week-old infant referred by the general pediatrician for evaluation of early-onset movement abnormalities characterized by dystonia, ataxia and intermittent hemiplegic episodes concerning for a neuromuscular or movement disorder, and chromosomal microarray (CMA) was previously performed and reported as nondiagnostic; given the clinical presentation and a positive family history in an older sibling with multiple congenital anomalies, whole exome sequencing (WES) is being pursued to evaluate for an underlying genetic etiology, pre-test counseling was completed with a genetic counselor and post-test follow-up is planned, and testing is being ordered with coverage through BCBS_FEP."
    },
    {
        "id": "Case9408",
        "patient_info": "The 17-year-old patient is undergoing whole exome sequencing (WES) at the request of a medical geneticist for evaluation of epileptic encephalopathy with onset before three years of age; chromosomal microarray (CMA) testing was previously performed and was nondiagnostic. There is a family history of a persistent and severe immunologic or hematologic disorder in the patient's mother, and pre-test counseling was completed with plans for post-test follow-up with a genetic counselor. Testing will be submitted to Blue Cross Blue Shield Federal Employee Program (FEP) for coverage."
    },
    {
        "id": "Case4067",
        "patient_info": "The 5-year-old was referred by a developmental pediatrician for evaluation of significant hypotonia and whole exome sequencing (WES) has been ordered to assess for an underlying genetic etiology; prior chromosomal karyotype testing was nondiagnostic, and there is a family history of sudden unexplained death in a paternal uncle before age 35 that raises concern for a heritable disorder, with the family reporting coverage through UHC."
    },
    {
        "id": "Case4982",
        "patient_info": "An 11-year-old with a history of Hirschsprung disease was referred by a developmental pediatrician for genetic evaluation and is being considered for whole exome sequencing (WES) to evaluate for an underlying genetic etiology; prior fluorescence in situ hybridization (FISH) testing was nondiagnostic, and the patient has a sibling who developed epileptic encephalopathy before age three, raising concern for a heritable syndromic or neurodevelopmental condition; the family has coverage through UHC and has met with a genetic counselor multiple times for pre-test counseling with plans for post-test result disclosure and multidisciplinary follow-up."
    },
    {
        "id": "Case8710",
        "patient_info": "The patient is a 12-year-old who was referred by a developmental pediatrician for genetic evaluation of autism spectrum disorder with at least one additional abnormality affecting another organ system, and whole exome sequencing (WES) has been requested to investigate an underlying genetic etiology. Prior karyotype testing was nondiagnostic. There is a reported family history of neurologic disease in a paternal uncle characterized by dystonia and ataxia. No pre-test genetic counseling was documented and the family plans to proceed with testing with coverage through UHC."
    },
    {
        "id": "Case13613",
        "patient_info": "At 22 weeks' gestation fetal imaging identified multiple structural anomalies and the pregnancy was referred by neurology for evaluation with whole exome sequencing (WES) to assess potential genetic etiologies that could inform postnatal management and counseling. Fragile X testing was previously performed and was nondiagnostic. There is a family history of dysmorphic features in a maternal aunt, and pre-test discussion occurred with a genetic specialist and testing will be pursued with coverage through UHC."
    },
    {
        "id": "Case1501",
        "patient_info": "The patient is a 2-year-old child referred by a developmental pediatrician for evaluation of multiple congenital anomalies and ongoing developmental concerns, and prior karyotype testing was nondiagnostic; there is a family history of Long QT syndrome in the mother. Whole exome sequencing (WES) is being ordered to identify an underlying genetic etiology, pre-test genetic counseling has been completed with plans for post-test follow-up, and the family has coverage through UHC."
    },
    {
        "id": "Case10451",
        "patient_info": "The patient is a 10-year-old with moderate to severe intellectual disability diagnosed in childhood who was referred by neurology for whole exome sequencing (WES) to evaluate an unexplained neurodevelopmental disorder; prior chromosomal microarray (CMA) testing was nondiagnostic. There is a family history of a sibling who had a brief resolved unexplained event characterized by altered level of responsiveness with cyanosis, pallor, and irregular breathing. The neurologist placed the order, there is no documentation of prior genetic counseling, and testing will be pursued with coverage through UHC."
    },
    {
        "id": "Case4262",
        "patient_info": "The five-week-old infant presents with multiple congenital anomalies that do not fit a well-delineated genetic syndrome and was referred by the patient's oncologist for diagnostic whole exome sequencing (WES); prior karyotype testing was nondiagnostic, and family history is notable for a sibling who experienced a brief resolved unexplained event with altered responsiveness, cyanosis, pallor, and irregular breathing, pre-test genetic counseling has been completed and post-test follow-up with genetics is planned, and testing will proceed with coverage through BCBS_FEP."
    },
    {
        "id": "Case19321",
        "patient_info": "The patient is a 1-year-old referred by a neurologist for evaluation of a complex neurodevelopmental disorder with features concerning for autism spectrum disorder, and whole exome sequencing (WES) is being pursued to investigate a possible genetic etiology; prior chromosomal microarray (CMA) testing was nondiagnostic. A maternal aunt is reported to have multiple congenital anomalies, pre-test genetic counseling was completed, and plans are in place for post-test follow-up, with coverage through UHC."
    },
    {
        "id": "Case11795",
        "patient_info": "The patient is a three-week-old infant referred by a cardiologist for evaluation of a high-risk brief resolved unexplained event (BRUE) with a markedly abnormal electrocardiogram concerning for channelopathy, significant arrhythmia, cardiomyopathy, myocarditis, or structural heart disease. Chromosomal microarray (CMA) was previously performed and was nondiagnostic, so whole exome sequencing (WES) is being ordered to evaluate for an underlying genetic cause. There is a family history of a sibling with moderate to severe intellectual disability diagnosed in childhood, pre-test genetic counseling has been completed with plans for post-test follow-up, and testing will be billed through BCBS_FEP."
    },
    {
        "id": "Case9349",
        "patient_info": "The patient is a 5-year-old with a congenital cardiac anomaly affecting a single organ system who was referred by a cardiologist for genetic evaluation and whole exome sequencing (WES) because the family history raises concern for an inherited etiology, specifically a paternal uncle who experienced sudden unexplained death before age 35; prior fluorescence in situ hybridization testing was nondiagnostic, pre-test counseling was completed with a genetic counselor and plans for post-test follow-up are confirmed, and testing will be pursued with coverage through BCBS_FEP."
    },
    {
        "id": "Case14127",
        "patient_info": "Seventeen-year-old referred to medical genetics for evaluation of global developmental delay (GDD) with lifelong cognitive and adaptive deficits, and whole exome sequencing (WES) is being pursued to investigate an underlying genetic etiology; prior fluorescence in situ hybridization (FISH) testing was nondiagnostic. There is a family history of epileptic encephalopathy in a sibling with onset before three years of age. The medical geneticist is coordinating testing, the patient saw a genetic counselor for pre-test counseling and will return for post-test counseling, and the testing will be submitted with coverage through UHC."
    },
    {
        "id": "Case950",
        "patient_info": "The 38-year-old patient is being evaluated by a medical geneticist for unexplained epileptic encephalopathy with onset before three years of age and has not had prior epilepsy multigene panel testing, so whole exome sequencing (WES) is being pursued to look for an underlying genetic cause; karyotype testing was previously performed and was nondiagnostic. The family history is notable for an uncle with metastatic, high-risk prostate cancer with intraductal/cribriform histology. The patient has seen a genetic counselor multiple times, has coverage through UHC, and plans are in place for post-test counseling and follow-up."
    },
    {
        "id": "Case15834",
        "patient_info": "The infant is being evaluated for concern for autism spectrum disorder based on early signs and was referred by the primary care physician for genetic assessment; whole exome sequencing (WES) has been ordered to assess for an underlying genetic etiology, and prior Fragile X testing was nondiagnostic. There is a family history of a maternal aunt with a congenital anomaly. Pre-test counseling was completed with a genetic specialist and testing will be pursued with coverage through UHC."
    },
    {
        "id": "Case14371",
        "patient_info": "An 11-year-old with complex neurodevelopmental disorder and autism spectrum disorder is being evaluated by the general pediatrician who has ordered whole exome sequencing (WES) to investigate an underlying genetic etiology; prior Fragile X testing was nondiagnostic, and there is a family history of a maternal aunt with a persistent severe immunologic disorder, which may inform interpretation of results, and the family met with a genetic counselor before testing with plans for post-test follow-up, with coverage through UHC."
    },
    {
        "id": "Case1130",
        "patient_info": "The 68-year-old patient was referred by cardiology for evaluation of persistent seizures and is undergoing whole exome sequencing (WES) to assess for an underlying genetic etiology; prior fluorescence in situ hybridization (FISH) testing was nondiagnostic, and the patient reports a sister with ovarian, fallopian tube, or peritoneal carcinoma in the family, which was reviewed during counseling. The patient has seen a genetic counselor multiple times with plans for post-test follow-up and testing is being arranged with coverage through UHC."
    },
    {
        "id": "Case11514",
        "patient_info": "The 10-year-old patient is being evaluated for conjugated hyperbilirubinemia not attributable to total parenteral nutrition and whole exome sequencing (WES) has been requested to investigate a potential genetic cause of cholestatic liver disease; a chromosomal microarray (CMA) was previously performed and was nondiagnostic. There is a family history of an inborn error of metabolism in a cousin, which raises concern for an inherited metabolic disorder contributing to the hepatic phenotype. The test was ordered by the patient's oncologist, coverage is through UHC, and there is no documentation of pre-test genetic counseling."
    },
    {
        "id": "Case13675",
        "patient_info": "The patient is an 8-week-old infant referred by a neonatologist for evaluation of significant congenital hearing and/or visual impairment identified in early infancy, and whole genome sequencing (WGS) is being pursued for diagnostic clarification; prior fluorescence in situ hybridization testing was nondiagnostic. The family history is notable for a father with long QT syndrome, which will be considered in interpretation of any cardiac-associated findings. There is no documentation of pre-test genetic counseling and testing is being requested with coverage through UHC with planned post-test follow-up by the neonatal team."
    },
    {
        "id": "Case3474",
        "patient_info": "The patient is a 5-year-old who was evaluated by a medical geneticist for congenital choanal atresia and whole genome sequencing (WGS) is being ordered to assess for an underlying genetic etiology or syndromic association given the structural airway anomaly and a reported older sibling with developmental delay, prior karyotype testing was nondiagnostic, pre-test genetic counseling has been completed on multiple occasions with plans for post-test follow-up, and testing is being pursued with coverage through UHC."
    },
    {
        "id": "Case13983",
        "patient_info": "The patient is a 7-week-old infant being evaluated for a high-risk brief resolved unexplained event (BRUE) with a significantly abnormal electrocardiogram (ECG) that raises concern for an underlying channelopathy, arrhythmia, cardiomyopathy, myocarditis, or structural heart disease, and whole genome sequencing (WGS) is being pursued at the request of the ordering gynecologist given the concerning cardiac findings and family history. Prior fluorescent in situ hybridization testing was nondiagnostic. The maternal uncle has a history of unexplained developmental regression reported as unrelated to autism or epilepsy and this family history prompted consideration of an inherited etiology. Pre-test counseling was completed with a genetic counselor and plans are in place for post-test follow-up, and testing will be billed through BCBS_FEP."
    },
    {
        "id": "Case11981",
        "patient_info": "The patient is a 9-year-old child referred by neurology for evaluation of a history of abnormal muscle tone noted in infancy that has persisted with ongoing motor concerns and developmental surveillance; fragile X testing was previously performed and was nondiagnostic. Whole genome sequencing (WGS) is being requested to evaluate for an underlying genetic etiology after pre-test discussion with a genetic specialist, and the family reports coverage through UHC. Family history is notable for a maternal uncle with a persistent severe immunologic disorder, which has been considered in the differential and counseling."
    },
    {
        "id": "Case10427",
        "patient_info": "An 8-week-old infant was referred by a neurologist for evaluation of significant hypotonia, and whole genome sequencing (WGS) is being requested to identify a potential genetic etiology; fluorescence in situ hybridization (FISH) testing was previously performed and was nondiagnostic. The family history is notable for an older sibling who experienced unexplained developmental regression not related to autism or epilepsy. Pre-test counseling has been completed with a genetic counselor on multiple occasions and post-test follow-up is planned, and testing is being ordered with coverage through UHC."
    },
    {
        "id": "Case17822",
        "patient_info": "The patient is a 13-year-old referred to medical genetics for evaluation of multiple congenital anomalies affecting different organ systems, and whole genome sequencing (WGS) has been ordered as the next-tier diagnostic test after a nondiagnostic chromosomal microarray (CMA). The family history is notable for a sibling with short stature, genetic counseling was declined prior to testing, and the order was placed by a medical geneticist with coverage through UHC, with plans to review results and coordinate further evaluation and management as indicated."
    },
    {
        "id": "Case6747",
        "patient_info": "A 12-year-old child with multiple congenital anomalies is undergoing whole genome sequencing (WGS) ordered by the medical geneticist to evaluate a suspected genetic etiology. Chromosomal microarray (CMA) testing was previously performed and was nondiagnostic. The family reports a sibling with developmental delay, pre-test counseling has been completed and post-test counseling is planned, and the patient has coverage through BCBS_FEP."
    },
    {
        "id": "Case15938",
        "patient_info": "The patient is a one-week-old infant under the care of a neonatologist being evaluated for conjugated hyperbilirubinemia not related to total parenteral nutrition and whole-genome sequencing (WGS) is being considered to identify a potential genetic cholestatic or metabolic etiology; prior karyotype testing was nondiagnostic, there is a family history of a sibling with unexplained developmental regression unrelated to autism or epilepsy, no pretest genetic counseling is documented, and the family has coverage through UHC."
    },
    {
        "id": "Case18868",
        "patient_info": "The patient is a 41-year-old with a diagnosis of primary peritoneal carcinoma who was evaluated by a medical geneticist and for whom whole genome sequencing (WGS) has been ordered to assess for an underlying hereditary cancer predisposition; prior karyotype testing was nondiagnostic. Her mother reportedly has a persistent and severe hematologic disorder, which raised concern for a heritable syndrome affecting cancer and hematologic risk. Coverage is through Cigna, and there was no documented record of pre-test genetic counseling in the materials provided."
    },
    {
        "id": "Case2162",
        "patient_info": "An infant aged 7 weeks was referred by a general practitioner for whole genome sequencing (WGS) to evaluate multiple congenital anomalies affecting multiple organ systems identified at birth; prior Fragile X testing was nondiagnostic, the family history is notable for an older sibling with autism spectrum disorder, pre-test genetic counseling has been completed with plans for post-test follow-up, and the family has coverage through BCBS_FEP."
    },
    {
        "id": "Case7447",
        "patient_info": "At 33 weeks' gestation, fetal imaging raises concern for an isolated severe congenital heart defect and the cardiologist has ordered whole genome sequencing (WGS) to evaluate for a possible genetic etiology and to guide postnatal management; prior fragile X testing was nondiagnostic, family history is notable for a maternal aunt with triple-negative breast cancer, there is no documentation of pre-test genetic counseling, and coverage is through BCBS_FEP."
    },
    {
        "id": "Case5380",
        "patient_info": "An 8-week-old infant is referred by neurology for evaluation of high-risk brief resolved unexplained events (BRUE) with recurrent witnessed seizure-like episodes, and whole genome sequencing (WGS) is requested to assess for an underlying genetic cause; prior chromosomal microarray (CMA) testing was nondiagnostic, and there is a maternal history of short stature as a growth abnormality, the family declined pre-test genetic counseling, and testing will be pursued with coverage through UHC."
    },
    {
        "id": "Case3465",
        "patient_info": "The patient is a 2-year-old being evaluated by a medical geneticist for developmental delay and intellectual disability without a specific syndrome suspected, and whole genome sequencing (WGS) has been ordered to search for an underlying genetic etiology with coverage through UHC, prior Fragile X testing was nondiagnostic, and there is a family history of Long QT syndrome in the patient's father; pre-test counseling was completed with a genetic counselor and plans are in place for post-test counseling and result review."
    },
    {
        "id": "Case5885",
        "patient_info": "An 11-year-old patient was referred by neurology for evaluation of a major abnormality affecting at least one organ system and whole genome sequencing (WGS) is requested to investigate an underlying genetic cause, Fragile X testing was previously performed and was nondiagnostic, and there is a family history of long QT syndrome in the mother; pre-test counseling was discussed with a genetic specialist and plans for post-test follow-up are in place with coverage through UHC."
    },
    {
        "id": "Case19162",
        "patient_info": "The infant is a neonate presenting with complex neurologic abnormalities including dystonia, ataxia, and asymmetric weakness suggestive of neonatal hemiplegia and was referred by a medical geneticist for whole genome sequencing (WGS) to evaluate for an underlying genetic or metabolic cause. Fragile X testing was previously performed and was nondiagnostic, and there is a family history of an inborn error of metabolism in a sibling. Pre-test counseling was completed with a genetic counselor and post-test follow-up is planned, and testing will be pursued with coverage through BCBS_FEP."
    },
    {
        "id": "Case7604",
        "patient_info": "The neonate was referred by a neurologist for evaluation of multiple congenital anomalies affecting several organ systems and whole genome sequencing (WGS) has been ordered to evaluate for an underlying genetic etiology. Fluorescence in situ hybridization (FISH) testing was performed previously and was nondiagnostic. There is a family history notable for an older sibling with multiple congenital anomalies. The family has coverage through UHC and they declined genetic counseling at this time."
    },
    {
        "id": "Case8661",
        "patient_info": "The patient is a 7-year-old referred by the child's neurologist for evaluation of a significant hearing or visual impairment identified in childhood and whole genome sequencing (WGS) is requested to investigate a possible genetic cause. Fragile X testing was previously performed and was nondiagnostic. There is a family history of a sibling who developed an epileptic encephalopathy before three years of age. Genetic counseling was offered but the family declined pre-test counseling; testing is being pursued with coverage through UHC and plans are in place to provide post-test genetic counseling and genetics follow-up if results are informative."
    },
    {
        "id": "Case10850",
        "patient_info": "The patient is a 13-year-old with global developmental delay being evaluated by a developmental pediatrician and whole genome sequencing (WGS) has been ordered to search for an underlying genetic etiology; prior fluorescence in situ hybridization (FISH) testing was nondiagnostic, there is a family history of an aunt with dysmorphic features, and the family completed pre-test genetic counseling with plans for post-test follow-up, with testing pursued through UHC coverage."
    },
    {
        "id": "Case13406",
        "patient_info": "The infant is 6 weeks of age and is being evaluated for concern of global developmental delay, with a family history notable for a sibling who experienced a brief resolved unexplained event described as altered level of responsiveness with cyanosis, pallor, and irregular breathing; chromosomal microarray (CMA) was previously performed and was nondiagnostic. Whole genome sequencing (WGS) has been ordered by a medical geneticist to assess for an underlying genetic etiology, pre-test counseling has been completed, and the family will follow up with the genetic counselor after results, with testing submitted for coverage through UHC."
    },
    {
        "id": "Case7014",
        "patient_info": "An infant aged seven weeks was referred by neurology for evaluation of multiple congenital anomalies that do not fit a well-delineated genetic syndrome, and whole genome sequencing (WGS) is being requested to identify an underlying genetic etiology. Prior karyotype testing was nondiagnostic. There is a family history of a maternal aunt with a congenital anomaly. Pre-test genetic counseling was completed with a genetic specialist and results will be reviewed with the family and the neurology team, with coverage through UHC."
    },
    {
        "id": "Case6451",
        "patient_info": "The 7-week-old infant was evaluated by a developmental pediatrician for significant hypotonia and whole genome sequencing (WGS) is being pursued to identify a potential genetic cause. The family reports that the mother has a history of a persistent, severe immunologic or hematologic disorder. A prior karyotype was nondiagnostic. Pre-test counseling has been completed and post-test follow-up with genetics is planned, and testing is being obtained with coverage through UHC."
    },
    {
        "id": "Case18281",
        "patient_info": "The patient is a 6-year-old child referred by the cardiologist for evaluation of multiple congenital anomalies that do not fit a well-delineated genetic syndrome, and the cardiologist has ordered whole genome sequencing (WGS) to assess for an underlying genetic etiology. Fragile X testing was previously performed and was nondiagnostic. There is a family history of an inborn error of metabolism in a sibling. No genetic counseling was conducted prior to testing and the family has coverage through UHC."
    },
    {
        "id": "Case10363",
        "patient_info": "The patient is a 7-year-old child with a congenital anomaly present since birth who was referred by the general practitioner for whole genome sequencing (WGS) after fluorescence in situ hybridization (FISH) testing was nondiagnostic. The family history is notable for a maternal aunt with pancreatic cancer and the family has coverage through UHC. The patient has been seen multiple times by a genetic counselor for pre-test counseling and plans for post-test follow-up are in place. WGS is being pursued to provide a comprehensive genomic evaluation given the longstanding congenital findings and prior nondiagnostic targeted testing."
    },
    {
        "id": "Case15557",
        "patient_info": "A 15-year-old referred by neurology for evaluation of a congenital anomaly present since birth is being evaluated with whole genome sequencing (WGS) to identify an underlying genetic etiology, and prior fluorescent in situ hybridization (FISH) testing was nondiagnostic; the patient has a sibling with a similar congenital anomaly and has been seen by a genetic counselor multiple times with plans for post-test counseling and coordination of care, and testing is being pursued with coverage through UHC."
    },
    {
        "id": "Case4512",
        "patient_info": "The patient is a 21-year-old referred by the primary care physician for evaluation of a major congenital cardiac anomaly present since birth, and whole genome sequencing (WGS) is being pursued to identify a potential genetic etiology; there is a family history of a sibling who experienced a brief resolved unexplained event characterized by altered level of responsiveness with cyanosis, pallor, and irregular breathing which raised concern for a heritable predisposition, and no prior genetic testing has been performed, pre-test counseling was completed with a genetic counselor and a post-test visit is planned with testing submitted with coverage through BCBS_FEP."
    },
    {
        "id": "Case1428",
        "patient_info": "The three-week-old infant is being evaluated by a medical geneticist for Hirschsprung disease and whole genome sequencing (WGS) has been ordered to assess for an underlying genetic cause given a family history of an older sibling with severe intellectual disability diagnosed by age 18. Fragile X testing was previously performed and was nondiagnostic, and there is no documented pre-test genetic counseling. Testing will be submitted through UHC for coverage."
    },
    {
        "id": "Case5605",
        "patient_info": "The patient is an 11-year-old being evaluated for a major congenital cardiac anomaly and was referred by an obstetrician for whole genome sequencing (WGS) to assess for an underlying genetic cause. A prior chromosomal microarray (CMA) was nondiagnostic, pre-test counseling was completed with a genetic specialist, and insurance coverage is through BCBS_FEP. Family history is notable for a maternal aunt with pancreatic cancer."
    },
    {
        "id": "Case14155",
        "patient_info": "The child is a 7-year-old referred by neurology for evaluation of autism spectrum disorder and whole genome sequencing (WGS) has been requested to assess for genetic contributors to the neurodevelopmental presentation. There is a family history notable for a maternal uncle with a persistent, severe immunologic disorder, which raised concern for an inherited predisposition that might overlap with neurodevelopmental features. There has been no prior genetic testing, and pre-test genetic counseling was declined by the family; testing is being pursued with coverage through Cigna."
    },
    {
        "id": "Case3223",
        "patient_info": "The 75-year-old woman was referred by her general practitioner for BRCA1 and BRCA2 testing because her sister had epithelial ovarian cancer, and she has a history of a major congenital cardiac anomaly for which a chromosomal microarray (CMA) was previously performed and reported as nondiagnostic. There is no documentation of pre-test genetic counseling, and she has coverage through BCBS_FEP."
    },
    {
        "id": "Case14195",
        "patient_info": "An 18-year-old with a history of a major congenital cardiac anomaly is being evaluated by an oncologist and referred for BRCA1/2 testing because of a family history that includes a maternal uncle with dystonia and ataxia, prior karyotype testing was nondiagnostic, no pretest genetic counseling has been conducted, and the patient has coverage through BCBS_FEP."
    },
    {
        "id": "Case22",
        "patient_info": "An 18-year-old man is undergoing BRCA1/2 testing to evaluate for a possible hereditary predisposition in the setting of high-risk prostate cancer with intraductal/cribriform histology and metastatic disease, with testing ordered by his neurologist; his father also had metastatic high-risk prostate cancer with intraductal/cribriform features. A prior chromosomal microarray (CMA) was nondiagnostic. He completed pre-test counseling and will return for post-test follow-up with a genetic counselor, and the testing is being pursued with coverage through the Blue Cross Blue Shield Federal Employee Program (BCBS_FEP)."
    },
    {
        "id": "Case19255",
        "patient_info": "The patient is a 38-year-old woman with a history of two separate primary breast cancers who was referred by her neurologist for BRCA1/2 testing to evaluate for hereditary breast and ovarian cancer predisposition, she reports a family history notable for a father with metastatic prostate cancer, prior fluorescence in situ hybridization testing was nondiagnostic, and pre-test counseling was completed with a genetic specialist with testing to be pursued with coverage through UHC."
    },
    {
        "id": "Case15458",
        "patient_info": "The patient is a 19-year-old woman with a personal history of breast cancer who is being evaluated for BRCA1 and BRCA2 testing because of a family history that includes ovarian cancer in a maternal aunt and a close relative with metastatic or intraductal/cribriform prostate cancer, prior fluorescence in situ hybridization (FISH) testing was nondiagnostic, the testing was ordered by a nurse practitioner, and the patient completed pre-test genetic counseling with plans for post-test follow-up, with coverage through BCBS_FEP."
    },
    {
        "id": "Case6867",
        "patient_info": "She is a 50-year-old woman with a personal history of breast cancer who presents for BRCA1 and BRCA2 testing because she reports a brother with metastatic prostate cancer demonstrating intraductal features and a mother who was diagnosed with breast cancer at age 50; she has no prior genetic testing documentation. She was referred by a nurse practitioner and has had multiple pre-test counseling visits with a genetic counselor, and the planned BRCA1/2 testing will be pursued with coverage through BCBS_FEP."
    },
    {
        "id": "Case16126",
        "patient_info": "The patient is a 6-week-old infant being evaluated for multiple congenital anomalies and BRCA1 and BRCA2 testing has been ordered by a gynecologist. FISH testing was previously performed and was nondiagnostic, the parents are reported to be consanguineous, pre-test counseling has been completed with plans for post-test follow-up with a genetic counselor, and testing will be billed through BCBS_FEP."
    },
    {
        "id": "Case2211",
        "patient_info": "A 21-year-old patient is referred by a general practitioner for BRCA1 and BRCA2 (breast cancer susceptibility) testing because of a personal history of a primary solid tumor and reports of at least two additional affected blood relatives on the same side of the family; the patient states that the mother carries a known BRCA2 pathogenic variant. No prior genetic testing has been performed, and pre-test counseling was completed with a genetic specialist with plans for post-test follow-up. Testing is being requested through UHC to clarify hereditary cancer risk and to guide management for this young adult."
    },
    {
        "id": "Case14408",
        "patient_info": "The patient is a 75-year-old who was referred by a family medicine physician for BRCA1/2 testing because of dysmorphic features and a family history notable for a brother with breast cancer; there is no prior genetic testing, pre-test counseling was completed and post-test follow-up with a genetic counselor is planned, and testing will be billed through Cigna."
    },
    {
        "id": "Case16246",
        "patient_info": "The patient is a 35-year-old woman with a personal history of breast cancer who meets criteria for hereditary testing because her diagnosis occurred before age 50, and she is being referred by her gynecologist for BRCA1 and BRCA2 testing with coverage through UHC; she reports a family history notable for an uncle with pancreatic cancer, prior karyotype testing was performed and was nondiagnostic, and no pre-test genetic counseling has been conducted."
    },
    {
        "id": "Case2007",
        "patient_info": "An 18-year-old patient with metastatic breast cancer was referred by a family medicine physician for BRCA1 and BRCA2 testing because of a family history notable for the patient's mother having breast cancer at age 50 or younger, chromosomal microarray (CMA) was previously performed and was nondiagnostic, and no other prior genetic testing information is available; the patient completed pre-test counseling and will return for post-test counseling, and testing will be billed through BCBS_FEP."
    },
    {
        "id": "Case15570",
        "patient_info": "The patient is a 15-year-old being followed by a general pediatrician for Hirschsprung disease and the clinician has requested BRCA1 and BRCA2 testing despite the pediatric gastrointestinal indication. Prior karyotype testing was nondiagnostic and the family history is notable for a mother with bipolar disorder, with no other cancer history documented. There is no documentation of pre-test genetic counseling and the test was ordered with coverage through the Blue Cross Blue Shield Federal Employee Program (FEP)."
    },
    {
        "id": "Case6478",
        "patient_info": "A 52-year-old man with metastatic prostate cancer is being referred by his general practitioner for germline BRCA1 and BRCA2 testing because of a family history notable for a father with pancreatic cancer; he has had no prior genetic testing, pre-test genetic counseling was not completed, and testing is being pursued with coverage through UHC to inform therapeutic options and cascade testing for at-risk relatives with plans for post-test counseling and oncology follow-up once results are available."
    },
    {
        "id": "Case3677",
        "patient_info": "She is a 46-year-old woman with a personal history of breast cancer who is undergoing BRCA1/2 testing because of a close relative with pancreatic cancer and multiple other primary solid tumors on the same side of the family; prior chromosomal microarray (CMA) testing was nondiagnostic. The patient was referred by a nurse practitioner and completed pre-test genetic counseling with plans for post-test follow-up, and testing will be billed to UHC. Her family history is notable for a mother with pancreatic cancer and at least two additional affected relatives on the maternal side."
    },
    {
        "id": "Case3581",
        "patient_info": "The patient is a 69-year-old adult for whom BRCA1 and BRCA2 testing has been ordered by the cardiologist to evaluate a history of significant hearing or visual impairment that was diagnosed by age 18. Prior fluorescence in situ hybridization testing was nondiagnostic, and the family history is notable for a sibling who experienced a brief resolved unexplained event characterized by altered responsiveness, cyanosis, pallor, and irregular breathing. No pre-test genetic counseling has been conducted and testing is being pursued with coverage through Cigna."
    },
    {
        "id": "Case15202",
        "patient_info": "The patient is a 65-year-old woman with a history of malignant phyllodes tumors of the breast who was referred by her gynecologist for BRCA1 and BRCA2 testing to evaluate possible hereditary breast and ovarian cancer risk, and she reports a sister with a persistent and severe immunologic or hematologic disorder in the family; Fragile X testing was previously performed and was nondiagnostic, pre-test counseling was completed with a genetic specialist with plans for post-test follow-up, and she has coverage through BCBS_FEP."
    },
    {
        "id": "Case18257",
        "patient_info": "The 64-year-old patient has a history of breast cancer diagnosed at age 50 or younger and is being evaluated for BRCA1/2 testing to assess hereditary breast and ovarian cancer risk. Chromosomal microarray (CMA) testing was previously performed and was nondiagnostic, family history is notable for a sibling with short stature, the test was ordered by the patient's general practitioner, there is no documentation of prior genetic counseling, and coverage is through Cigna."
    },
    {
        "id": "Case12792",
        "patient_info": "A 12-year-old was referred by a family medicine physician for BRCA1/2 testing in the setting of congenital choanal atresia and a reported growth abnormality in the mother. Prior fluorescent in situ hybridization (FISH) testing was nondiagnostic. Pre-test genetic counseling has been completed and post-test follow-up is planned, and testing will be billed through BCBS_FEP."
    },
    {
        "id": "Case14226",
        "patient_info": "A 55-year-old patient is being evaluated by oncology for germline BRCA1 and BRCA2 (BRCA1/2) testing because they have a personal history of a primary solid tumor other than basal or squamous cell skin cancer and risk assessment using Tyrer-Cuzick, BRCAPro, or Penn II calculators demonstrates a 2.5% or greater likelihood of a BRCA pathogenic variant; the patient has not undergone prior genetic testing and no pre-test genetic counseling was completed, and family history is notable for a mother with a persistent, severe hematologic or immunologic disorder, with testing being pursued with coverage through Cigna and results to be reviewed by the oncology team to inform management."
    },
    {
        "id": "Case5303",
        "patient_info": "The 37-year-old patient was referred by neurology for BRCA1 and BRCA2 testing in the setting of a major abnormality affecting at least one organ system and a family history notable for a brother who died suddenly and unexpectedly before age 35; no prior genetic testing has been performed and no pre-test genetic counseling was conducted, and the patient has coverage through UHC."
    },
    {
        "id": "Case2666",
        "patient_info": "A 21-year-old woman with a major congenital cardiac anomaly is undergoing BRCA1/2 testing at the request of her obstetrician, and prior fluorescence in situ hybridization (FISH) testing was nondiagnostic; she reports a father with metastatic prostate cancer prompting consideration of hereditary cancer evaluation, pre-test counseling was completed with a genetic specialist and plans for post-test follow-up are in place, and she has coverage through the Blue Cross Blue Shield Federal Employee Program (FEP)."
    },
    {
        "id": "Case3592",
        "patient_info": "The patient is a neonate evaluated by a developmental pediatrician for unexplained epileptic encephalopathy with neonatal onset and no prior epilepsy multigene panel testing; chromosomal microarray (CMA) testing for developmental disorders is being requested. A prior chromosomal microarray was nondiagnostic. There is a family history of an older sibling with unexplained developmental regression unrelated to autism or epilepsy. Pre-test counseling was discussed with a genetic specialist and post-test follow-up is planned, and testing is being submitted with coverage through Cigna."
    },
    {
        "id": "Case17595",
        "patient_info": "A 3-year-old child with significant hearing and visual impairment diagnosed by 18 years of age is being evaluated with chromosomal microarray (CMA) testing to assess for genomic causes of early-onset sensory impairment and associated developmental risk, and the test was ordered by a gynecologist; there is no prior genetic testing information, family history is notable for an uncle who had moderate to profound intellectual disability diagnosed by age 18, pre-test genetic counseling has been completed with plans for post-test follow-up, and the family has coverage through BCBS_FEP."
    },
    {
        "id": "Case5834",
        "patient_info": "The patient is 67 years old and is under the care of neurology for a lifelong history of severe intellectual disability diagnosed by age 18 and is being referred for chromosomal microarray (CMA) testing to evaluate a genomic etiology for the developmental disorder. No prior genetic testing has been performed. Pre-test counseling has been completed with a genetic counselor on multiple occasions and plans for post-test follow-up were discussed. The family history is notable for the patient's mother having had ovarian cancer and testing is being requested with coverage through the Blue Cross Blue Shield Federal Employee Program (BCBS_FEP)."
    },
    {
        "id": "Case15820",
        "patient_info": "The patient is a 31-year-old adult followed by neurology for developmental delay and intellectual disability without a suspected specific syndrome, and chromosomal microarray (CMA) has been ordered to evaluate for underlying copy number variants; no prior genetic testing has been reported, and the patient has completed multiple pre-test counseling sessions with a genetic counselor with plans for post-test follow-up, with insurance coverage through Cigna, and a pertinent family history of a mother who was diagnosed with breast cancer before age 50."
    },
    {
        "id": "Case17929",
        "patient_info": "Referred by a neurologist, a 7-year-old child covered by UHC is being evaluated for a major abnormality affecting at least one organ system and tumor chromosomal microarray (CMA) testing has been requested to assess for genomic imbalance after prior karyotype testing was nondiagnostic, the family history is notable for a known BRCA1/2 pathogenic variant identified in the mother and a maternal aunt, and the child has had multiple pretest counseling sessions with a genetic counselor with plans for post-test follow-up with neurology and genetics."
    },
    {
        "id": "Case17196",
        "patient_info": "The patient is a 63-year-old referred by the oncologist for chromosomal microarray (CMA) testing to evaluate a longstanding neuropsychiatric presentation with features suggestive of bipolar disorder, schizophrenia, or obsessive-compulsive disorder. Previous karyotype testing was nondiagnostic. The family history is notable for a sibling who had significant hearing or visual impairment diagnosed by age 18. No pre-test genetic counseling has been conducted and the test is being requested with coverage through the Blue Cross Blue Shield Federal Employee Program (BCBS FEP)."
    },
    {
        "id": "Case11855",
        "patient_info": "The patient is a 14-year-old being evaluated by a developmental pediatrician for a congenital anomaly affecting a single organ system with concern for an underlying genetic etiology, and chromosomal microarray (CMA) is being ordered to assess for copy number variants associated with developmental disorders; Fragile X testing was previously performed and was nondiagnostic. There is a family history notable for a maternal aunt with triple-negative breast cancer, which was discussed as part of the risk assessment during pre-test counseling. Pre-test counseling was completed with a genetic specialist and plans for post-test follow-up were made, and testing will be pursued with coverage through UHC."
    },
    {
        "id": "Case12834",
        "patient_info": "The patient is a 16-year-old referred by a developmental pediatrician for evaluation of a complex neurodevelopmental disorder affecting at least one organ system, and chromosomal microarray (CMA) testing has been ordered although the requisition specifies a tumor-type rather than a germline assay; prior Fragile X testing was nondiagnostic. There is a family history notable for a maternal uncle with a movement disorder described as dystonia and ataxia, genetic counseling is not documented in the record, and testing will be billed through Cigna."
    },
    {
        "id": "Case10075",
        "patient_info": "A four-week-old infant was seen by a developmental pediatrician for meconium ileus and consideration of chromosomal microarray (CMA) testing to evaluate for an underlying chromosomal or genetic etiology. Prior chromosomal microarray testing was nondiagnostic and there is a family history of an inborn error of metabolism in a sibling, raising concern for a heritable disorder. Pre-test counseling was completed with a genetic specialist and arrangements for post-test follow-up were discussed, and testing will be pursued with coverage through BCBS_FEP."
    },
    {
        "id": "Case9773",
        "patient_info": "The two-year-old is undergoing evaluation for severe intellectual disability with chromosomal microarray (CMA) ordered to assess for genomic copy number changes; there is no prior genetic testing on record. The study was ordered by the child's oncologist given concern for an underlying genetic etiology and there is a family history of a maternal aunt with a persistent and severe immunologic disorder. The family has coverage through the Blue Cross Blue Shield Federal Employee Program (FEP), and they completed pre-test genetic counseling with plans to return for post-test counseling after results are available."
    }
]